WuXi Biologics Earns CDMO Leadership Awards for the Ninth Straight Year
WuXi Biologics has once again reinforced its leadership position in the global biologics outsourcing sector, announcing that it has been named “Biologics CDMO of the Year” in the Large CDMO category at the 2026 CDMO Leadership Awards. In addition to this top honor, the company earned recognition across several key performance categories, including Best Scaling Support, Best Analytical Services, Best Overall Staff, and Best Project Management for large biologics CDMOs.
This latest achievement marks the ninth consecutive year that WuXi Biologics has been honored at the CDMO Leadership Awards, a distinction that highlights the company’s sustained excellence, innovation, and reliability in supporting global biopharmaceutical partners. The awards, produced by Life Science Connect and hosted by Outsourced Pharma in collaboration with the Tufts Center for the Study of Drug Development, are widely regarded as one of the most respected benchmarks for performance in the contract development and manufacturing organization (CDMO) industry.
Sustained Recognition Reflecting Industry Trust
The consistent recognition of WuXi Biologics over nearly a decade underscores the strong trust that global pharmaceutical and biotechnology companies place in its integrated capabilities. These awards are based on independent research and customer feedback, making them a meaningful indicator of real-world performance and client satisfaction.
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, emphasized that the repeated recognition reflects both the company’s technological leadership and the dedication of its global workforce of more than 13,000 employees. He noted that WuXi Biologics remains focused on advancing integrated technology platforms, enhancing manufacturing excellence, and leveraging digital innovation to help partners accelerate drug development timelines and deliver life-saving biologics to patients worldwide.
Expansive and Complex Project Portfolio
One of the defining features of WuXi Biologics’ leadership in the CRDMO space is the scale and diversity of its project portfolio. As of the end of 2025, the company had accumulated a total of 945 integrated projects on its platform, making it one of the largest and most comprehensive biologics pipelines managed by a CDMO globally.
Notably, more than half of these projects involve complex biologic modalities, including bispecific and multispecific antibodies as well as antibody-drug conjugates (ADCs). These advanced therapeutic formats represent the cutting edge of modern biopharmaceutical innovation, often requiring sophisticated development processes and specialized manufacturing capabilities.
WuXi Biologics’ ability to manage such a high proportion of complex molecules highlights its deep technical expertise and its commitment to staying at the forefront of biologics innovation.
Accelerating Development Timelines
A critical differentiator for WuXi Biologics lies in its ability to significantly shorten development timelines compared to industry norms. Leveraging its integrated technology platforms and accumulated expertise in molecule and process development, the company has achieved notable efficiencies across key stages of the drug development lifecycle.
The timeline from DNA to Investigational New Drug (IND) application has been reduced to approximately six months, compared with the typical industry range of 10 to 12 months. Similarly, the transition from IND to Biologics License Application (BLA) submission has been shortened to around 15 months, well below the industry average of 24 to 36 months.
In manufacturing, the company has streamlined the process from technology transfer to process performance qualification (PPQ), achieving a standard timeline of six months and an accelerated timeline of just 3.5 months. This compares favorably to industry timelines that often exceed 12 months, demonstrating WuXi Biologics’ ability to deliver speed without compromising quality.
Advanced Manufacturing Capabilities
WuXi Biologics has developed a comprehensive and flexible manufacturing strategy designed to meet the evolving needs of its global client base. Central to this strategy is the use of large-scale single-use bioreactors (SUBs), which range in capacity from 2,000 liters to 5,000 liters.
By combining multiple SUBs, the company can achieve large-scale production volumes of up to 16,000 liters, enabling it to support both clinical and commercial manufacturing requirements. This modular approach allows for scalability and agility, ensuring that production capacity can be adjusted in response to changing market demands.
In addition to traditional manufacturing approaches, WuXi Biologics has introduced innovative bioprocessing technologies to further enhance productivity. These include WuXiUP™, a continuous bioprocessing platform, and WuXiUI™, an ultra-intensified fed-batch platform. Both technologies are designed to increase yield, reduce production time, and improve overall efficiency.
Another key innovation is WuXia™ TrueSite, a next-generation cell line development platform based on targeted integration (TI) technology. This system enables high and stable expression of monoclonal antibodies, achieving average titers exceeding 8.0 grams per liter and maintaining stability across 60 generations. Such performance is critical for ensuring consistent product quality in large-scale biologics manufacturing.
Proven Track Record in Quality and Compliance
WuXi Biologics’ reputation for excellence is further reinforced by its strong track record in quality and regulatory compliance. The company has achieved a 100% success rate in PPQ campaigns, demonstrating its ability to consistently deliver robust and reproducible manufacturing processes.
Since 2017, WuXi Biologics has completed more than 350 large-scale production batches, each ranging from 6,000 to 16,000 liters, for partners around the world. This extensive experience in large-scale manufacturing underscores the company’s capability to support commercial biologics production at scale.
Regulatory compliance is another area where WuXi Biologics excels. As of the end of 2025, the company had successfully passed 46 regulatory inspections conducted by major health authorities, including the U.S. Food and Drug Administration and the European Medicines Agency. Among these were 22 inspections by these two leading agencies.
The company also boasts a 100% pass rate for FDA Pre-License Inspections (PLI), a critical milestone in the approval process for new biologics manufacturing facilities. In total, WuXi Biologics operates 15 Good Manufacturing Practice (GMP)-certified facilities across its global network, with 136 facility license approvals and a perfect success rate in GMP inspections.
These achievements highlight the robustness of WuXi Biologics’ global quality system, which serves as a cornerstone of its value proposition and a key factor in building long-term partnerships with clients.
Driving Digital Transformation in Biologics
In addition to its strengths in manufacturing and process development, WuXi Biologics is at the forefront of digital innovation in the biopharmaceutical industry. The company has implemented digital solutions across its entire value chain, from early-stage research and development to manufacturing operations and customer engagement.
One of the key tools in this digital transformation is the use of Electronic Batch Records (EBR), which has enabled approximately 40% gains in productivity while ensuring data integrity and maintaining high product quality standards. Advanced planning systems have further contributed to operational efficiency, delivering improvements of around 20%.
More recently, WuXi Biologics introduced PatroLab™, an advanced digital twin platform designed to simulate and optimize bioprocesses. This technology allows for real-time monitoring and predictive analysis, helping to minimize process risks, enhance performance, and accelerate development timelines. By enabling a deeper understanding of manufacturing processes, PatroLab™ supports the consistent production of high-quality biologics.
Industry Recognition and Future Outlook
The continued success of WuXi Biologics at the CDMO Leadership Awards reflects not only its current capabilities but also its forward-looking strategy. By integrating cutting-edge technologies, maintaining rigorous quality standards, and embracing digital transformation, the company is well positioned to address the growing complexity of biologics development.
As the demand for biologic therapies continues to rise—driven by advancements in areas such as oncology, immunology, and rare diseases—CDMOs like WuXi Biologics play an increasingly critical role in enabling innovation and ensuring timely access to new treatments.
The company’s ability to deliver end-to-end solutions, from discovery through commercial manufacturing, makes it a preferred partner for global biopharmaceutical companies seeking to navigate the challenges of modern drug development.
The recognition of WuXi Biologics as “Biologics CDMO of the Year” for the ninth consecutive year is a testament to its sustained excellence, innovation, and commitment to client success. With a robust portfolio, advanced manufacturing technologies, strong regulatory track record, and a growing emphasis on digital innovation, the company continues to set new standards in the CRDMO industry.
As WuXi Biologics looks to the future, its focus on accelerating development timelines, enhancing scalability, and maintaining the highest levels of quality will remain central to its mission. By doing so, the company is not only strengthening its leadership position but also contributing to the advancement of global healthcare by enabling the delivery of life-saving biologic therapies to patients around the world.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
Source Link:https://www.wuxibiologics.com/
